Advances in gene-based vaccine platforms to address the COVID-19 pandemic

• Published in: Advanced drug delivery reviews Vol. 170; pp. 113 - 141
• Main Authors: Pushparajah, Deborah, Jimenez, Salma, Wong, Shirley, Alattas, Hibah, Nafissi, Nafiseh, Slavcev, Roderick A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2021
• Subjects: Animals; Clinical Trials as Topic - methods; Coronavirus; COVID-19; COVID-19 - epidemiology; COVID-19 - genetics; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - genetics; COVID-19 Vaccines - immunology; DNA vaccines; Humans; mRNA Vaccines; Non-replicative viral vaccines; Pandemics - prevention & control; Replicative viral vaccines; RNA vaccines; SARS-CoV-2; SARS-CoV-2 - drug effects; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Vaccines; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - genetics; Vaccines, Synthetic - immunology; Viral Vaccines - administration & dosage; Viral Vaccines - genetics; Viral Vaccines - immunology; ADE; SARS-CoV; MERS-CoV; Vaccines; SLE; TNF; LNP; COVID-19; SARS-CoV-2; Replicative viral vaccines; Th; a.a; RBD; Non-replicative viral vaccines; BGH; IL; ChAd; MV; EP; polyA; CMV; ACE2; Coronavirus; Lunar; RSV; AAV; IIV; VSV; MVA; MIV; ORF; E; DNA vaccines; M; N; DPP4; IFN; S; GBV; TLR; GC; WNV; tPA; GP; HAI; saRNA; OGN; HA; RNA vaccines
• ISSN: 0169-409X; 1872-8294
• DOI: 10.1016/j.addr.2021.01.003

The novel betacoronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has spread across the globe at an unprecedented rate since its first emergence in Wuhan City, China in December 2019. Scientific communities around the world have been rigorously working to develop a potent vaccine to combat COVID-19 (coronavirus disease 2019), employing conventional and novel vaccine strategies. Gene-based vaccine platforms based on viral vectors, DNA, and RNA, have shown promising results encompassing both humoral and cell-mediated immune responses in previous studies, supporting their implementation for COVID-19 vaccine development. In fact, the U.S. Food and Drug Administration (FDA) recently authorized the emergency use of two RNA-based COVID-19 vaccines. We review current gene-based vaccine candidates proceeding through clinical trials, including their antigenic targets, delivery vehicles, and route of administration. Important features of previous gene-based vaccine developments against other infectious diseases are discussed in guiding the design and development of effective vaccines against COVID-19 and future derivatives. [Display omitted]